Joel Cohen

Sofie Biosciences, Inc. operates as a diagnostics company that provides molecular imaging probes and devices to help scientists and physicians investigate the biology of disease. It combines the discovery and development of new PET imaging probes with innovative imaging systems and chemistry platforms to provide researchers and physicians with tools to better understand the biology of disease. The company was founded by Owen N. Witte, Michael E. Phelps, Jim Heath, Johannes Czernin, and Caius Radu in 2008 and is headquartered in Culver City, CA.

Athos Therapeutics, Inc. is a biotech company based in Torrance, CA. Athos Therapeutics develops small molecule therapeutics for immune-mediated diseases using artificial intelligence-generated innovative chemistry and computational platforms. The private company identifies novel drug targets by integrating clinical and molecular datasets into the biological network of a disease and matches them to its small molecule computational chemistry platform. Ath-63, the company's lead drug compound, is moving into a phase I human clinical trial for patients with inflammatory bowel disease in Q1 2022 at the Cleveland Clinic. Other pipeline programs include drugs for lupus and various types of cancers. The company was founded in 2019 by Michael Jung, Allan J. Pantuck, and Dimitrios Iliopoulos, who has been the CEO since then.